Immunovant, Inc.

Immunovant, Inc. is a clinical-stage immunology company developing FcRn-targeted therapies for autoimmune diseases driven by pathogenic IgG antibodies. Its lead candidate, IMVT-1402, and earlier program batoclimab are being advanced for multiple specialty indications, with the company currently focused on clinical development rather than commercial sales.

9.09

— Immunovant, Inc.
	%
Lead FcRn inhibitor programs	80% Clinical and pre-commercial development of IMVT-1402 and batoclimab for autoimmune diseases.
Clinical development services	15% Trial design, execution, and regulatory preparation for autoimmune indications.
Commercial readiness and launch planning	5% Buildout of sales, marketing, distribution, and supply arrangements ahead of approval.

Immunovant does not yet sell approved products, so its near-term “customers” are mainly investigators, clinical trial...

Specialist physiciansprimary
Rheumatologists, neurologists, endocrinologists, dermatologists and other specialists who would prescribe approved FcRn therapies for autoimmune disease patients.
Clinical trial sites and investigatorsprimary
Hospitals and physician practices that enroll and monitor patients in Immunovant's studies and determine execution speed.
Third-party payorssecondary
Commercial insurers and public payors that would determine access, coverage, and utilization after approval.
Regulatory authoritiesprimary
FDA and foreign regulators that review clinical data and determine whether products can be commercialized.

Immunovant is headquartered in the United States and expects its initial commercial organization to be built in the U.S...

•United States is the planned initial commercial market
•Clinical and regulatory activity is centered in the U.S.
•Batoclimab manufacturing includes facilities in the U.S. and South Korea
•IMVT-1402 supply depends on third-party CMOs for clinical trials
•Potential future collaborations may extend commercialization outside the U.S.

The company’s strategy is to advance IMVT-1402 through clinical development and regulatory approval while preserving...

Clinical advancement of IMVT-1402short-term

Approval depends on generating convincing efficacy and safety data in autoimmune indications.

Commercial readinessmedium-term

The company needs sales, marketing, distribution and reimbursement capabilities before launch.

External manufacturing and supply chain managementshort-term

Clinical and future commercial supply depends on third-party manufacturers and devices.

Immunovant is a pre-revenue biotech, so its value depends on successful clinical outcomes, regulatory approval, and...

critical

Clinical development failure

The company has no approved products and depends on positive trial results for IMVT-1402 and batoclimab.

Scope: Lead programs
Materiality: high

high

Regulatory delay or rejection

Approval is required before any product revenue can be generated.

Scope: FDA and foreign regulators
Materiality: high

high

Manufacturing and supply chain disruption

The company relies on CMOs and third-party suppliers for drug substance, drug product, and devices.

Scope: U.S. and South Korea manufacturing
Materiality: high

high

Commercial competition

Autoimmune disease markets are crowded with approved therapies and pipeline competitors.

Scope: FcRn and autoimmune indications
Materiality: high

high

Financing and dilution risk

The company expects continued net losses and needs capital to fund development and launch.

Scope: Pre-revenue operations
Materiality: high

R&D accruals and clinical trial estimates

Affects quarterly operating expense and loss volatility

Third-party manufacturing commitments

Affects future cash outflows and expense recognition

Revenue recognition for future collaborations

Could materially affect future revenue timing

Stock-based compensation

Affects reported operating loss and dilution analysis

Immunovant, Inc.

Clinical development failure

Regulatory delay or rejection

Manufacturing and supply chain disruption

Commercial competition

Financing and dilution risk

AIM ImmunoTech Inc.

Imunon, Inc.

IOVANCE BIOTHERAPEUTICS, INC.

IMMUNIC, INC.

Roivant Sciences Ltd.

Immunome Inc.